On January 17, local time, Novo Nordisk announced the main results of the Phase 3b clinical trial STEP UP. In the STEP UP obesity trial, once-weekly subcutaneous injection of 7.2 mg semaglutide resulted in a 20.7% weight loss at 72 weeks and an 18.7% weight loss regardless of treatment compliance. The trial met its primary endpoint, with 7.2 mg of semaglutide demonstrating statistically significant and superior weight loss compared with placebo at week 72.